Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent cliffs, product recalls, and opioid litigation make Teva Pharmaceutical Industries’ disclosures uniquely dense. Digging through a 300-page document for segment margins or litigation reserves is tedious. That’s why investors search for TEVA SEC filings explained simply—and why Stock Titan’s AI turns raw EDGAR data into clear insights you can trust.
Our platform streams every filing the minute it hits EDGAR and pairs it with AI-powered summaries, key-metric tables, and risk flags. Whether you need a TEVA quarterly earnings report 10-Q filing or want to monitor TEVA Form 4 insider transactions real-time, we’ve got you covered. Here’s what you’ll find:
- 10-K & 10-Q—full text plus a TEVA annual report 10-K simplified dashboard and deep TEVA earnings report filing analysis.
- Form 4—alerts on TEVA insider trading Form 4 transactions and granular views of TEVA executive stock transactions Form 4.
- 8-K—real-time headlines with TEVA 8-K material events explained, from FDA warning letters to debt covenant updates.
- DEF 14A—a concise take on the TEVA proxy statement executive compensation discussion and board governance shifts.
Need help understanding TEVA SEC documents with AI? Stock Titan highlights how pricing pressure impacts cash flow, where biosimilar milestones sit, and when litigation accruals change. Professionals use these insights to track segment performance, spot option grants before approval catalysts, and compare R&D outlays quarter to quarter—without wading through endless footnotes.
Teva Pharmaceutical Industries Limited has amended its senior unsecured sustainability-linked revolving credit agreement to extend the stated maturity date of the lenders’ commitments and loans by one year, from April 29, 2027 to April 29, 2028. This extension is the second one-year extension permitted under the original April 29, 2022 agreement and helps keep this revolving credit facility available for a longer period.
The amendment also updates key financial covenants. The Company’s maximum permitted leverage ratio for Q4 2025 and thereafter is set at 4.25x, with potential increases if Teva completes or starts certain material transactions. If Teva achieves Investment Grade Status and no event of default is continuing, the maximum leverage and minimum interest cover ratio covenants will no longer apply; if Investment Grade Status is later lost or an event of default occurs, these covenants will be reinstated for future testing dates.
Teva Pharmaceutical Industries executive exercises options and sells shares
On December 9, 2025, a Teva Pharmaceutical Industries Ltd. executive, identified as an officer serving as Exec. VP, European Commercial, reported multiple equity transactions. The executive exercised 100,457 stock options at an exercise price of $18.61 per share and another 15,011 stock options at an exercise price of $16.99 per share, receiving the same number of Teva ordinary shares. On the same day, the executive sold 115,468 ordinary shares at a weighted average price of $28.6757 per share, leaving 48,384 ordinary shares beneficially owned directly after the transactions. The filing notes that Teva ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
Teva Pharmaceutical Industries executive Mark Sabag, Executive Vice President, International Markets Commercial, reported an option exercise and related share sales. On 12/09/2025, he exercised stock options to buy 118,724 Ordinary Shares at an exercise price of $18.61 per share, increasing his directly held shares.
That same day, he sold 118,724 Ordinary Shares at a weighted average price of $28.748 per share and an additional 98,168 Ordinary Shares at a weighted average price of $28.7026 per share, both through multiple transactions within narrow price ranges. After these transactions, he directly owned 52,828 Ordinary Shares and held no remaining stock options from this grant. Each Ordinary Share may be represented by one American Depositary Share.
Teva Pharmaceutical Industries insider plans Rule 144 share sale. A holder has filed to sell 216,892 ordinary shares of Teva through Citigroup Global Markets on the NYSE, with an aggregate market value of $6,230,750.00 as of the notice. Teva had 1,147,282,512 ordinary shares outstanding, providing context for the size of the planned sale.
The securities to be sold were acquired in two ways: 98,168 shares were received on 03/01/2021 in a rollover transaction from Teva Pharmaceutical Industries Limited, and 118,724 shares were obtained via a cashless exercise of stock options, with cash payment dated 12/09/2025. The seller represents that they are not aware of any undisclosed material adverse information about Teva’s current or prospective operations.
Teva Pharmaceutical Industries reported a planned sale of restricted stock under Rule 144. The filing covers the potential sale of 115,468 ordinary shares through Citigroup Global Markets Inc. on the NYSE, with an aggregate market value of $3,311,131.04. The shares relate to ordinary shares acquired on 12/09/2025 via a cashless exercise of stock options, with cash noted as the form of payment.
The filing states that the person for whose account the securities may be sold represents that they are not aware of any material adverse, non-public information about Teva’s current or prospective operations.
Teva Pharmaceutical Industries director equity update: A Teva director reported the vesting and settlement of 4,804 restricted share units into the same number of ordinary shares on 12/02/2025, shown as an "M" (conversion) transaction. Following this transaction, the director beneficially owns 4,804 ordinary shares, held directly.
These restricted share units were originally granted on December 2, 2024 and vested on December 2, 2025. Each restricted share unit entitled the holder to receive one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share. Teva’s ordinary shares may also be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
Teva Pharmaceutical Industries Ltd. director reports share sale. A reporting person serving as a director of Teva Pharmaceutical Industries Ltd. (TEVA) sold 50,000 Ordinary Shares on 11/26/2025 in an open-market transaction coded "S" for sale. The shares were sold at a weighted average price of
After this transaction, the reporting person is shown as beneficially owning 445,000 Ordinary Shares indirectly through Swiftcurrent Master Fund Ltd. and 105,315 Ordinary Shares directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share, and that certain indirect holdings are disclaimed except for any indirect pecuniary interest.
Teva Pharmaceutical Industries (TEVA) executive Christine Fox reported equity compensation activity and a related share sale. On 11/20/2025, 63,492 restricted share units vested and were settled into the same number of ordinary shares. On the same date, she sold 28,229 ordinary shares at $24.7803 per share, with the filing stating this represented shares required to be sold to cover tax withholding obligations tied to the vesting.
The sale was carried out under a Rule 10b5-1 trading plan adopted on August 11, 2025. After these transactions, Fox directly beneficially owned 63,647 ordinary shares and held 126,984 restricted share units that may settle into additional ordinary shares or their cash value under the company’s compensation arrangements.
Teva Pharmaceutical Industries Ltd. insider plans share sale under Rule 144. A holder has filed to sell 28,229 ordinary shares through Citigroup Global Markets Inc. on the NYSE, with an aggregate market value of $699,523.09. The filing notes that 1,147,282,512 ordinary shares were outstanding at the time of the notice.
The seller acquired 63,492 ordinary shares on 11/20/2025 via restricted stock vesting from Teva as compensation, and payment was characterized as compensation rather than cash. Over the past three months, the same person sold 30,000 ordinary shares on 11/14/2025 for gross proceeds of $753,321.00. By signing, the seller represents they are not aware of undisclosed material adverse information about Teva’s operations.
Teva Pharmaceutical Industries Ltd. (TEVA) reported an insider stock sale by its EVP, Head of U.S. Commercial. On 11/14/2025, the executive sold 30,000 Ordinary Shares in an open market transaction at a price of $25.1107 per share, reported under transaction code "S" for a sale. After this transaction, the executive beneficially owns 28,384 Ordinary Shares, held directly. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
FAQ
What is the current stock price of Teva Pharm (TEVA)?
What is the market cap of Teva Pharm (TEVA)?
